Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein ...
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...
The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...
The combination of decitabine (DAC) and cytarabine, acclarithromycin, and granulocyte colony-stimulating factor (CAG) vs CAG alone showed greater efficacy among older patients with acute myeloid ...
An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety ...
Yatiri Bio, a precision medicine company utilizing an AI-driven proteomic platform (ProteoCharts™) to identify therapeutically sensitive patient populations, reports results from a blinded ...
SurvivorNet on MSN
A new all oral treatment for AML on the horizon for patients struggling to withstand chemo
Inqovi for AML treatment ...
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
Amgen acquires Dark Blue Therapeutics to fight Acute Myeloid Leukemia. See how this $840M deal aims to deliver first-in-class ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results